Executive leadership at TITAN PHARMACEUTICALS.
Research analysts who have asked questions during TITAN PHARMACEUTICALS earnings calls.
Recent press releases and 8-K filings for TTNP.
Titan Pharmaceuticals Completes Merger and Management Changes
TTNP
M&A
Management Change
Delisting/Listing Issues
- Titan Pharmaceuticals, Inc. (TTNP) completed its previously announced business combination on October 1, 2025, resulting in TTNP becoming a direct wholly owned subsidiary of Black Titan Corporation.
- As a consequence of the merger, TTNP common stock is anticipated to cease trading on the Nasdaq Capital Market, and Black Titan Corporation's Ordinary Shares are expected to begin trading on Nasdaq commencing October 2, 2025.
- Effective October 1, 2025, TTNP's directors and officers resigned, and Chay Weei Jye was appointed as the sole director and acting secretary of TTNP.
- Stockholders of TTNP immediately prior to the merger ceased to have any rights as stockholders of TTNP, other than the right to receive the Stockholder Consideration.
Oct 1, 2025, 8:20 PM
Quarterly earnings call transcripts for TITAN PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more